LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 30, 2015) - GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug ...
GlaxoSmithKline and Theravance’s Breo has been recommended for approval by an FDA advisory committee for asthma, but only in adults. Breo is already approved to treat chronic obstructive pulmonary ...
Last month, GlaxoSmithKline ($GSK) CEO Andrew Witty told reporters that its new, slow-starter lung drugs were finally picking up steam. That's something the company ...
MISSISSAUGA, ON, July 10, 2013 /CNW/ - BREO™ ELLIPTA™ (fluticasone furoate/vilanterol) has been approved in Canada for the long-term once-daily maintenance treatment of airflow obstruction in patients ...
LONDON and SAN FRANCISCO, April 30, 2015 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback